Allarity Therapeutics, Inc.
ALLR
$1.08
$0.0050.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 244.24% | -31.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 180.34% | -22.57% | |||
| Operating Income | -180.34% | 22.57% | |||
| Income Before Tax | 37.72% | -634.62% | |||
| Income Tax Expenses | 100.00% | -- | |||
| Earnings from Continuing Operations | 35.69% | -611.48% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 35.69% | -611.48% | |||
| EBIT | -180.34% | 22.57% | |||
| EBITDA | -180.84% | 22.70% | |||
| EPS Basic | 77.69% | -130.71% | |||
| Normalized Basic EPS | -19.77% | 55.96% | |||
| EPS Diluted | 77.69% | -130.71% | |||
| Normalized Diluted EPS | -19.77% | 55.96% | |||
| Average Basic Shares Outstanding | 174.86% | 215.60% | |||
| Average Diluted Shares Outstanding | 174.86% | 215.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||